Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Minsud Plans Private Placement of Up to CAD 500,000

Minsud Plans Private Placement of Up to CAD 500,000

BitgetBitget2026/11/05 14:36
  • Minsud Resources announced Nov. 5, 2026, plans for a non-brokered private placement raising up to approximately CAD 500,000.
  • The offering comprises up to 1,515,152 units priced at CAD 0.33 each.
  • Each unit includes one common share and one warrant to purchase another share at CAD 0.435 for five years from issuance.
  • Net proceeds will fund continued exploration at the Chita Valley Project, general working capital and corporate purposes.
  • Completion is subject to TSX Venture Exchange acceptance.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Minsud Resources Corp. published the original content used to generate this news brief via CNW (Ref. ID: 202611050935CANADANWCANADAPR_C8141) on November 05, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.

NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.

华尔街见闻•2026/11/09 22:12